Business
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY, March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2022 ended December 31, 2022.\n\n \n \n \n \n \n \n\n \nRecent Highlights:\nAnnounced positive top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. The results demonstrated the generalizability of the PreTRM® test-and-treat strategy in achieving meaningful clinical results in widely diverse U.S. populations toward significant improvement in neonatal health outcomes and hospital length-of-stay.Announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes), which, based on rigorous clinical utility health economic analysis, illustrated the impact of Sera's test-and-treat strategy and its specific benefits in underserved racial and ethnic populations. By combining the PreTRM® Test with enhanced prenatal care management, real progress may be possible in better serving these populations to enable better medical outcomes.Validated preeclampsia risk predictor, with results made available publicly and being prepared for submission to a scientific journal.Surpassed the required 2,800 PRIME study subject enrollment, which enables the interim look analysis by year end.\"We are pleased with the growing body of data showing the clinical utility and cost effectiveness of the PreTRM® Test in mitigating the negative health and economic consequences of preterm delivery,\" said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. \"The exciting AVERT PRETERM TRIAL results are being prepared for submission to a scientific journal for publication. We believe this provides meaningful evidence of the value of our test in improving the health of moms and babies. We are excited to pursue our mission to work with doctors, patients and health systems in creating a better standard of care in pregnancies.\"\nFourth Quarter 2022 Financial Results\nFourth quarter 2022 revenue of $65,000 compared to...